Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Merck Sharp + Dohme Corp.

Ra Pharmaceuticals, Inc.

Istituto Di Ricerche Biologia Molecolare P. Angeletti Spa

Immacolata Conte

Frank Narjes

Ian Stansfield

Stefania Colarusso

Thomas Joseph Tucker

Alonso Ricardo

Elisabetta Bianchi

Yusheng Xiong

Eric J Gilbert

Mark W Embrey

Nicolas Cedric Boyer

Sookhee Nicole Ha

Angela Dawn Kerekes

Joerg Habermann

Raffaele Ingenito

Aurash Shahripour

Hyewon Youm

Danila Branca

Chengwei Wu

Alessia Santoprete

Willy Costantini

Joseph R Stringer

Derek M LaPlaca

Caterina Ercolani

Roberto Costante

Michael Rowley

Simona Ponzi

Giovanni Migliaccio

Maria Del Rosario Rico Ferreira

Claudio Giuliano

Marco Pompei

Gessica Filocamo, Legal Representative

Veronica Suriano, Legal Representative

Angela Mackay

Provided herein are cyclic polypeptide compounds that can, e.g., bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) and optionally also inhibit interaction between human PCSK9 and human low density lipoprotein receptor (LDLR), and pharmaceutical compositions comprising one or more of these compounds. Also provided are methods of reducing LDL cholesterol level in a subject in need thereof that include administering to the subject one or more of the cyclic polypeptide compounds or a pharmaceutical composition provided herein.

Cyclic polypeptides for PCSK9 inhibition

The present invention is directed to compounds of formula (I): where X, Y, R, Rand Rare defined therein, which can act as modulators of viral replication and/or virus production, especially of the hepatitis C virus (HCV).

Modulators of HCV replication

A class of macrocyclic compounds of formula (I), wherein R, A, Ar, B, D, F, M, Q, Q, W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection. 

Therapeutic compounds

The present invention relates to indole compounds of the formula (I): wherein R, R, R, R, A, E and X are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections. 

Indole derivatives as antiviral agents

The present invention relates to tetracyclic indole compounds of formula (I): wherein R, R, A, Ar, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus.

Tetracyclic indole derivatives as antiviral agents

Growing community of inventors

Rome, Italy

Immacolata Conte